RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update
02 August 2023 - 2:30PM
RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a
specialty pharmaceutical company focused on the commercialization
of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%,
today announced that the Company will release its second quarter
2023 financial results and provide a commercial update on Monday,
August 14, 2023, before U.S. financial markets open.
Brian Markison, Chief Executive Officer, James
“JD” Schaub, Chief Operating Officer, and Mike DePetris, Principal
Accounting Officer, will host a conference call as follows:
Date |
|
Monday, August 14, 2023 |
Time |
|
8:30 a.m. ET |
Register* (audio only) |
|
Click here |
Webcast (live and replay) |
|
https://ir.rvlpharma.com/ under the “Investors & News”
section |
|
|
|
* Conference call participants should register to obtain their
dial-in and passcode details. Please be sure to register using a
valid email address.
IMPORTANT SAFETY
INFORMATION
INDICATION
UPNEEQ® (oxymetazoline hydrochloride ophthalmic
solution), 0.1% is indicated for the treatment of acquired
blepharoptosis in adults.
WARNINGS AND PRECAUTIONS
- Ptosis may be associated with
neurologic or orbital diseases such as stroke and/or cerebral
aneurysm, Horner syndrome, myasthenia gravis, external
ophthalmoplegia, orbital infection and orbital masses.
Consideration should be given to these conditions in the presence
of ptosis with decreased levator muscle function and/or other
neurologic signs.
- Alpha-adrenergic agonists as a
class may impact blood pressure. Advise UPNEEQ patients with
cardiovascular disease, orthostatic hypotension, and/or
uncontrolled hypertension or hypotension to seek medical care if
their condition worsens.
- Use UPNEEQ with caution in patients
with cerebral or coronary insufficiency or Sjögren’s syndrome.
Advise patients to seek medical care if signs and symptoms of
potentiation of vascular insufficiency develop.
- UPNEEQ may increase the risk of
angle closure glaucoma in patients with untreated narrow-angle
glaucoma. Advise patients to seek immediate medical care if signs
and symptoms of acute narrow-angle glaucoma develop.
- Patients should not touch the tip
of the single patient-use container to their eye or to any surface,
in order to avoid eye injury or contamination of the solution.
ADVERSE REACTIONS
Adverse reactions that occurred in 1-5% of
subjects treated with UPNEEQ were punctate keratitis, conjunctival
hyperemia, dry eye, blurred vision, instillation site pain, eye
irritation and headache.
DRUG INTERACTIONS
- Alpha-adrenergic agonists, as a
class, may impact blood pressure. Caution in using drugs such as
betablockers, anti-hypertensives, and/or cardiac glycosides is
advised. Caution should also be exercised in patients receiving
alpha adrenergic receptor antagonists such as in the treatment of
cardiovascular disease, or benign prostatic hypertrophy.
- Caution is advised in patients
taking monoamine oxidase inhibitors which can affect the metabolism
and uptake of circulating amines.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty
pharmaceutical company focused on the commercialization of UPNEEQ®
(oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the
treatment of acquired blepharoptosis, or low-lying eyelid, in
adults. UPNEEQ is the first non-surgical treatment option approved
by the FDA for acquired blepharoptosis.
Investor and Media Relations for RVL Pharmaceuticals
plc
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
RVL Pharmaceuticals (NASDAQ:RVLP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
RVL Pharmaceuticals (NASDAQ:RVLP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024